Roche announced it will stop development of emugrobart after key studies failed to show consistent improvements in muscle growth and motor function. Separately, Genentech ended development of a muscle‑preserving antibody after early‑stage data fell short, prompting internal portfolio reallocation. Both decisions were disclosed to patient groups and investors and reflect mounting clinical challenges for therapies aimed at preserving or restoring muscle mass in genetic disorders. These program terminations underscore the difficulty of translating preclinical muscle biology into consistent clinical benefit and may prompt reassessment of trial endpoints and target validation strategies across neuromuscular and obesity programmes.